July 21, 2017
A labeling mix-up has prompted Bristol-Myers Squibb to recall 48,180 bottles of Eliquis (apixaban) 5-mg tablets. The July 19, 2017, US Food and Drug Administration (FDA) Enforcement Report states an Eliquis bottle labeled for 5-mg tablets actually contained lower-strength 2.5-mg tablets.
The affected 60-count bottles are from lot HN0063, which has a September 2019 expiration. The bottles were distributed throughout the United States.
Bristol-Myers Squibb voluntarily initiated the recall June 5, 2017. On July 11, the FDA designated it Class I, indicating use of the affected product could cause serious adverse health consequences or death.
Eliquis is a prescription factor Xa inhibitor used to reduce the risk of blood clots and stroke.